Hidradenitis suppurativa

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Hidradenitis suppurativa
Classification and external resources
Specialty Dermatology
ICD-10 L73.2
ICD-9-CM 705.83
DiseasesDB 5892
eMedicine emerg/259 med/2717 derm/892
Patient UK Hidradenitis suppurativa
MeSH D017497
[[[d:Lua error in Module:Wikidata at line 863: attempt to index field 'wikibase' (a nil value).|edit on Wikidata]]]

Hidradenitis suppurativa (HS) is a common (though rarely diagnosed), chronic skin disease characterized by clusters of abscesses or subcutaneous boil-like "infections" (oftentimes free of actual bacteria) that most commonly affects apocrine sweat gland bearing areas, such as the underarms, under the breasts, inner thighs, groin and buttocks.[1] The disease is not contagious. There are indications that it is hereditary among certain ethnic groups and autoimmune in nature. Onset is most common in the late teens and early 20's.

HS outbreaks are painful in tender areas and may persist for years with interspersed periods of inflammation, often culminating in sudden drainage of pus. This process often forms open wounds that will not heal and frequently leads to significant scarring. For unknown reasons, people with HS develop plugging of their apocrine glands.[2] Incision and drainage procedures may provide symptomatic relief. HS flares may be triggered by emotional/erotic stress, sweating, hormonal changes, heat and humidity, and the condition is exacerbated by friction from clothing.

Persistent lesions may lead to the formation of sinus tracts, or tunnels connecting the abscesses or infections under the skin.[3] At this stage, complete healing is usually not possible, and progression is variable, with some experiencing remission for months to years at a time, while others may worsen and require multiple surgeries. Bacterial infections and cellulitis (deep tissue inflammation) are other common complications of HS. Depression and physical pain are often seen with HS and can be difficult to manage.[4] HS often goes undiagnosed for years due to embarrassment causing delay in seeking treatment. Due to the "invisible" nature of it, it is frequently misdiagnosed.[4] There is currently no known cure nor any consistently effective treatment.

Carbon dioxide laser surgery has been shown as an effective treatment providing quality of life improvement, with peer reviewed articles showing an 80% chance of non recurrence in the surgically removed site.[citation needed] Lukewarm Sitz baths can provide great relief, gentle antiseptic skin cleansers and hydrogen peroxide assist in keeping affected areas free of bacteria.[citation needed] HS is an orphan disease due to lack of publicity and sparse research efforts. The incidence of HS is not well established, but has been estimated as being between 1:24 (4.1%) and 1:600 (0.2%).[5][medical citation needed]

Causes

The cause of HS remains unknown and experts disagree over proposed causes.[6]

Lesions occur in any body areas with hair follicle although intertriginous areas such as the axilla, groin, and perianal region are more commonly involved. This theory includes most of the following potentials indicators:[7]

The historical understanding of the disease suggests dysfunctional apocrine glands[11] or dysfunctional hair follicles,[12] possibly triggered by a blocked gland, create inflammation, pain, and a swollen lesion.

Triggering factors

There are several triggering factors that should be taken into consideration.

Predisposing factors

Stages

HS presents itself in three stages.[4][11] Due to the large spectrum of clinical severity and the severe impact on quality of life, a reliable method for evaluating HS severity is needed.

Hurley's staging system

This is historically the first classification system proposed, and is still in use for the classification of patients with skin/dermatologic diseases (i.e., psoriasis, HS, acne). Hurley separated patients into three groups based largely on the presence and extent of cicatrization and sinuses. It has been used as a basis for clinical trials in the past and is a useful basis to approach therapy for patients. These three stages are based on Hurley's staging system, which is simple and relies on the subjective extent of the diseased tissue the patient has. Hurley's three stages of hidradenitis suppurativa are as follows:[22]

Stage Characteristics
I Solitary or multiple isolated abscess formation without scarring or sinus tracts. (A few minor sites with rare inflammation; may be mistaken for acne.)
II Recurrent abscesses, single or multiple widely separated lesions, with sinus tract formation. (Frequent inflammation restrict movement and may require minor surgery such as incision and drainage.)
III Diffuse or broad involvement across a regional area with multiple interconnected sinus tracts and abscesses. (Inflammation of sites to the size of golf balls, or sometimes baseballs; scarring develops, including subcutaneous tracts of infection – see fistula. Obviously, patients at this stage may be unable to function.)

Sartorius staging system

The Sartorius staging system is more sophisticated than Hurley's. Sartorius et al. suggested that the Hurley system is not sophisticated enough to assess treatment effects in clinical trials during research. This classification allows for better dynamic monitoring of the disease severity in individual patients. The elements of this staging system are the following:[23]

  • Anatomic regions involved (axilla, groin gluteal or other region or infra-mammary region left or right)
  • Number and types of lesions involved (abscesses, nodules, fistulas(actually sinuses), scars, points for lesions of all regions involved)
  • The distance between lesions, in particular the longest distance between two relevant lesions (i.e., nodules and fistulas in each region or size if only one lesion present)
  • The presence of normal skin in between lesions (i.e., are all lesions clearly separated by normal skin?)

Points are accumulated in each of the above categories, and added to give both a regional and total score. In addition, the authors recommend adding a visual analog scale for pain or using the dermatology life quality index (DLQI, or the Skindex) when assessing HS.[24]

Treatments

Treatments may vary depending upon presentation and severity of the disease. Due to the poorly studied nature of this disease, the effectiveness of the drugs and therapies listed below is unclear, and patients should discuss all options with their physician or dermatologist. Nearly a quarter of patients state that nothing relieves their symptoms.[25] Possible treatments include the following:

Lifestyle

  • Changes in diet avoiding inflammatory foods.
  • Warm compresses with distilled vinegar water, and taking hot baths with distilled white vinegar in the water[26] hydrotherapy, balneotherapy.
  • Icing the inflamed area daily until pain reduction is noticed.

Medication

  • Antibiotics- taken orally, these are used for their anti-inflammatory properties rather than to treat infection. Most effective is a combination of rifampicin and clindamycin given concurrently for 2–3 months. This brings about remission in around three quarters of cases.[27] A few popular antibiotics used to treat hidradenitis suppurativa include tetracycline, minocycline, and clindamycin.[28]
  • Corticosteroid injections. Also known as intralesional steroids: can be particularly useful for localized disease, if the drug can be prevented from escaping via the sinuses.
  • Vitamin A supplementation
  • Anti-androgen therapy: hormonal therapy with cyproterone acetate and ethinyl estradiol proved effective in randomized, controlled trials. Dosages reported have been very high.[29]
  • Intravenous or subcutaneous infusion of anti-inflammatory (anti-TNF-alpha) drugs such as infliximab (Remicade), and etanercept (Enbrel).[30] This use of these drugs is not currently Food and Drug Administration (FDA) approved and is somewhat controversial, and therefore may not be covered by insurance.
  • TNF inhibitor: Studies have supported that various TNF inhibitors have a positive effect on hidradenitis suppurativa lesions.[31] There is a large efficacy and safety study of adalimumab registered with the FDA. It recruited 309 patients and is currently completed. The results have not yet been published. FDA cleared Adalimumab for the treatment for Hidradenitis suppurativa.[32] Humira adalimumab [33] is the first FDA approved drug for the treatment of HS.
  • Zinc gluconate taken orally has been shown to induce remission.[34]
  • Chlorhexidine (Hibiclens) plus an antibiotic soap for cleansing the skin surface. Covering sores with Metrolotion after medicated showers. These are considered to be general measures and are the foundation of any good medical treatment and management plan for hidradenitis suppurativa.[citation needed]
  • Topical clindamycin has been shown to have an effect in double-blind placebo controlled studies.[35]
  • Topical resorcinol is a keratolytic agent that targets the follicular keratin plug and has been shown to have efficacy in several case series studies.[36]
  • Topical isotretinoin is usually ineffective in people with HS and is more commonly known as a medication for the treatment of acne vulgaris. Individuals affected by HS who responded to isotretinoin treatment tended to have milder cases of the condition.[37]

Radiation

Electron beam radiotherapy has been a successful treatment of hidradenitis, especially in Europe; it is not a common treatment option in most of the United States, as radiation oncologists generally are disinclined to treating patients with non-malignant diseases because of the potential for secondary radiation-induced tumors in the long term.

Surgery

When the process becomes chronic, wide surgical excision is the procedure of choice. Wounds in the affected area do not heal by secondary intention, and immediate application of a split thickness skin graft is more appropriate.[7]

Laser hair removal

The 1064 nanometer wavelength laser for hair removal aids in the treatment of HS.[38] A randomized control study has shown improvement in HS lesions with the use of an Nd:YAG laser.[39]

Prognosis

In stage III disease, fistulas left undiscovered, undiagnosed, or untreated, can lead to the development of squamous cell carcinoma, a rare cancer, in the anus or other affected areas.[40][41] Other stage III chronic sequelae may also include anemia, multilocalized infections, amyloidosis, and arthropathy. Stage III complications have been known to lead to death, but clinical data is still uncertain.

Potential complications

History

  • In 1839, Velpeau identified and described hidradenitis suppurativa.[48]
  • In 1854, Verneuil described hidradenitis suppurativa as "Hidrosadénite Phlegmoneuse". This is how HS obtained its alternate name "Verneuil's disease".[49]
  • In 1922, Schiefferdecker hypothesized a pathogenic link between "Acne inversa" and human apocrine sweat glands.[50]
  • In 1956, Pillsbury wrote and published a medical journal article discussing hidradenitis suppurativa, describing the disease's main characteristics, dubbing them the "Acne triad: hidradenitis suppurativa, perifolliculitis capitis abscedens et suffodiens".[51] Pillsbury's research study was one of the first peer-reviewed journal articles to appear publicly with many details of hidradenitis suppurativa, which are still used and relied on today in the medical realm of research on this disease.
  • In 1975, Plewig and Kligman, following Pillsbury's research path, modified the "Acne triad", replacing it with the "Acne tetrad: acne triad, plus pilonidal sinus".[52] Plewig and Kligman's research follows in Pillsbury's footsteps, offering explanations of the symptoms associated with hidradenitis suppurativa.
  • In 1989, Plewig and Steger's research led them to rename hidradenitis suppurativa, calling it "Acne Inversa" – which is not still used today in medical terminology; although some individuals still use this outdated term.[53]

A surgeon from Paris, Velpeau described an unusual inflammatory process with formation of superficial axillary, sub-mammary and perianal abscesses in 1839. One of his colleagues also located in Paris, named Verneuil, coined the term “hidrosadénite phlegmoneuse” approximately 15 years later. This name for the disease reflects the former pathogenetic model of acne inversa, which is considered inflammation of sweat glands as the primary cause of hidradenitis suppurativa. In 1922 Schiefferdecker suspected a pathogenicassociation between acne inversa and apocrine sweat glands. In 1956 Pillsbury postulated follicular occlusion as the cause of acne inversa, which they grouped together with acne conglobata and perifolliculitis capitis abscendens et suffodiens (dissecting cellulitis of the scalp) as the "acne triad". Plewig and Kligman added another element to their acne triad, pilonidal sinus. Plewig et al. noted that this new "acne tetrad" includes all the elements found in the original "acne triad", in addition to a fourth element, pilonidal sinus. In 1989, Plewig and Steger introduced the term "acne inversa", indicating a follicular source of the disease and replacing older terms such as "Verneuil disease".

Author Year Findings
Velpeau 1839 First description of the hidradenitis suppurativa
Verneuil 1854 "Hidrosadénite phlegmoneuse"
Pillsbury 1956 Acne triad (hidradenitis suppurativa, perifolliculitis capitis abscendens et suffodiens, acne congoblata)
Plewig & Kligman 1975 Acne tetrad (acne triad + pilonidal sinus)
Plewig & Steger 1989 Acne inversa

Other names

Hidradenitis suppurativa has been referred to by multiple names in the literature, as well as in various cultures. Some of these are also used to describe different diseases, or specific instances of this disease.[4]

  • Acne conglobata – not really a synonym – this is a similar process but in classic acne areas of chest and back
  • Acne Inversa (AI) – a proposed new term[54][55] which has not gained widespread favor.[56]
  • Apocrine acne – an outdated term based on the disproven concept that apocrine glands are primarily involved, though many do suffer with apocrine gland infection
  • Apocrinitis – another outdate term based on the same thesis
  • Fox-den disease – a term not used in medical literature, based on the deep fox den / burrow – like sinuses
  • Hidradenitis Supportiva – a misspelling
  • Pyodermia fistulans significa – now considered archaic
  • Velpeau's disease – commemorating the surgeon who first described the disease in 1833
  • Verneuil's disease – recognizing the surgeon whose name is most often associated with the disorder as a result of his 1854–1865 studies[57]

Histology

Author Year Major Features
Plewig & Steger[53] 1989 Initial hyperkeratosis of the follicular infundibulum. Bacterial super-infection and follicle rupture. Granulomatous inflammatory reaction of the connective tissue. Apocrine and eccrine sweat glands secondarily involved.
Yu & Cook[58] 1990 Cysts and sinus tracts lined with epithelium, in part with hair shafts. Inflammation of apocrine sweat glands only if eccrine sweat glands and hair follicles are also inflamed.
Boer & Weltevreden[59] 1996 Primary inflammation of the follicular infundibulum. Apocrine sweat glands are secondarily involved.

References

  1. Alikhan, Ali; Lynch, Eisen (2009). "Hidradenitis suppurativa: a comprehensive review". J Am Acad Derm. 60 (4): 539–561. doi:10.1016/j.jaad.2008.11.911. PMID 19293006.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. Mayo Clinic Staff. "Causes". Mayo Clinic. Retrieved 19 September 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  3. "Mayo Clinic site". Retrieved 7 December 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  4. 4.0 4.1 4.2 4.3 "HS-USA :: What is Hidradenitis Suppurativa?". Retrieved 20 July 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  5. "HS-USA: Prevalence of Hidradenitis Suppurativa". Retrieved 8 July 2007.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  6. Medline Plus (2012). "Hidradenitis suppurativa". U.S. National Library of Medicine. Retrieved 19 September 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  7. 7.0 7.1 Schawartz's principles of surgery, 8th edition, self assessment an board review, chapter 15, the skin and subcutaneous tissue, question 16
  8. Mayo Clinic Staff (2012). "Definition". Mayo Clinic. Retrieved 19 September 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  9. Clinical trial number NCT00329823 for "Etanercept in Hidradenitis Suppurativa" at ClinicalTrials.gov
  10. Cusack C, Buckley C (2006). "Etanercept: effective in the management of hidradenitis suppurativa". Br J Dermatol. 154 (4): 726–9. doi:10.1111/j.1365-2133.2005.07067.x. PMID 16536817.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  11. 11.0 11.1 DermNet acne/hidradenitis-suppurativa
  12. "HSF – What is Hidradenitis Suppurativa? What is HS?". Retrieved 8 July 2007.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  13. 13.0 13.1 Slade DEM, Powell BW, Mortimer PS (2003). "Hidradenitis suppurativa: pathogenesis and management". Br J Plast Surg. 56 (5): 451–61. doi:10.1016/S0007-1226(03)00177-2. PMID 12890458.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  14. 14.0 14.1 Jemec GBE. Body weight in hidradenitis suppurativa. In: Marks R, Plewig G, editors. Acne and Related disorders. London: Martin Dunitz; 1989. pp. 375–6.
  15. Koning A, Lehmann C, Rompel R, Happle R (1999). "of Hidradenitis suppurativa". Dermatology. 198 (3): 261–4. doi:10.1159/000018126. PMID 10393449.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  16. Morgan WP, Leicester G (1979). "The role of depilation and deodorants in hidradenitis suppurativa". Br J Surg. 66 (12): 853–6. doi:10.1002/bjs.1800661206. PMID 509057.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  17. Stellon AJ, Wakeling M (1989). "Hidradenitis suppurativa associated with use of oral contraceptives". Br Med J. 298 (6665): 28–9. doi:10.1136/bmj.298.6665.28.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  18. Gupta AK, Knowles SR, Gupta MA, Jaunkalns R, Shear NH (1995). "Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium". J Am Acad Dermatol. 32 (2 Pt 2): 382–6. doi:10.1016/0190-9622(95)90410-7. PMID 7829746.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  19. Hidradenitis Suppurativa at eMedicine
  20. Der Werth JM, Williams HC, Raeburn JA (2000). "The clinical genetics of hidradenitis suppurativa revisited". Br J Dermatol. 142 (5): 947–53. doi:10.1046/j.1365-2133.2000.03476.x. PMID 10809853.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  21. Barth JH, Kealey T (1991). "Androgen metabolism by isolated human axillary apocrine glands in hidradenitis suppurativa". Br J Dermatol. 125 (4): 304–8. doi:10.1111/j.1365-2133.1991.tb14162.x. PMID 1954117.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  22. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. Marcel Dekker, New York, 1989, pp. 729–739.
  23. Sartorius K, Lapins J, Emtestam L, Jemec GB (2003). "Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa". Br J Dermatol. 149 (1): 211–213. doi:10.1046/j.1365-2133.2003.05390.x. PMID 12890229.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  24. Wolkenstein, P; Loundou, A; Barrau, K; Auquier, P; Revuz, J; Quality of Life Group of the French Society of Dermatology (2007). "Quality of life impairment in hidradenitis suppurativa: a study of 61 cases". Journal of the American Academy of Dermatology. 56 (4): 621–3. doi:10.1016/j.jaad.2006.08.061. PMID 17097366.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  25. "About Hidradenitis Suppurativa". abscesses.org. Retrieved 8 July 2007.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  26. Martinez F, Nos P, Benlloch S, Ponce J (2001). "Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab". Inflammatory Bowel Dis. 7 (4): 323–326. doi:10.1097/00054725-200111000-00008. PMID 11720323.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  27. Gener G; Canoui-Poitrine F; Revuz JE; et al. (2009). "Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients". Dermatology (Basel). 219 (2): 148–54. doi:10.1159/000228334. PMID 19590173.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  28. Scheinfeld N (2013). "Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients". Dermatology Online Journal. 19 (4): 1. PMID 24021361.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  29. Mortimer PS, Dawber RP, Gales MA, Moore RA (1986). "A double blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa". Br J Dermatol. 115 (3): 263–8. doi:10.1111/j.1365-2133.1986.tb05740.x. PMID 2944534.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  30. Cusack C, Buckley C (2006). "Etanercept: effective in the management of hidradenitis suppurativa". Br. J. Dermatol. 154 (4): 726–9. doi:10.1111/j.1365-2133.2005.07067.x. PMID 16536817.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  31. Haslund P, Lee RA, Jemec GB (November 2009). "Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors". Acta Derm. Venereol. 89 (6): 595–600. doi:10.2340/00015555-0747. PMID 19997689.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  32. Clinical trial number NCT01468207 for "Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (PIONEER I)" at ClinicalTrials.gov
  33. Scheinfeld N (2006). "Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab". J. Am. Acad. Dermatol. 55 (1): 163–4. doi:10.1016/j.jaad.2006.01.024. PMID 16781316.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  34. Anabelle Brocard, Anne-Chantal Knol, Amir Khammari, Brigitte Dréno (2007). "Hidradenitis Suppurativa and Zinc: A New Therapeutic Approach". Dermatology. 214 (4): 325–7. doi:10.1159/000100883. PMID 17460404.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  35. Clemmenson OJ (1983). "Topical treatment of hidradenitis suppurativa with clindamycin". Int J Dermatol. 22 (5): 325–8. doi:10.1111/j.1365-4362.1983.tb02150.x. PMID 6347922.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  36. Boer, J; Jemec, GB (2010). "Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa". Clin Exp Dermatol. 35 (1): 36–40. doi:10.1111/j.1365-2230.2009.03377.x. PMID 19549239.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  37. Nickle SB, Peterson N, Peterson M (April 2014). "Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin". J Clin Aesthet Dermatol. 7 (4): 22–34. PMC 3990537. PMID 24765227.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  38. "Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients". http://escholarship.org. Retrieved 4 March 2014. External link in |work= (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  39. Xu LY, Wright DR, Mahmoud BH, Ozog DM, Mehregan DA, Hamzavi IH (January 2011). "Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment". Arch Dermatol. 147 (1): 21–8. doi:10.1001/archdermatol.2010.245. PMID 20855672.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  40. Talmant JC, Bruant-Rodier C, Nunziata AC, Rodier JF, Wilk A (2006). "[Squamous cell carcinoma arising in Verneuil's disease: two cases and literature review]". Ann Chir Plast Esthet (in French). 51 (1): 82–6. doi:10.1016/j.anplas.2005.11.002. PMID 16488526.CS1 maint: multiple names: authors list (link) CS1 maint: unrecognized language (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  41. Short KA, Kalu G, Mortimer PS, Higgins EM (2005). "Vulval squamous cell carcinoma arising in chronic hidradenitis suppurativa". Clin. Exp. Dermatol. 30 (5): 481–3. doi:10.1111/j.1365-2230.2005.01875.x. PMID 16045671.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  42. Hurley HJJ. Apocrine glands. New York: McGraw Hill; 1979.
  43. Tennant F Jr, Bergeron JR, Stone OJ, Mullins JF (1968). "Anemia associated with hidradenitis suppurativa". Arch Dermatol. 98 (2): 138–40. doi:10.1001/archderm.98.2.138. PMID 5667225.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  44. Williams ST, Busby RC, DeMuth RJ, Nelson H (1991). "Perineal hidradenitis suppurativa: presentation of two unusual complications and a review". Ann Plast Surg. 26 (5): 456–62. doi:10.1097/00000637-199105000-00008. PMID 1952719.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  45. Lapins J, Ye W, Nyren O, Emtestam L (2001). "Incidence of cancer among patients with hidradenitis suppurativa". Arch Dermatol. 137 (6): 730–4. PMID 11405761.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  46. Moschella SL (1966). "Hidradenitis suppurativa. Complications resulting in death". JAMA. 198 (1): 201–3. doi:10.1001/jama.198.1.201. PMID 5953172.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  47. Vasey FB, Fenske NA, Clement GB, Bridgeford PH, Germain BF, Espinoza LR (1984). "Immunological studies of the arthritis of acne conglobata and hidradenitis suppurativa". Clin Exp Rheumatol. 2 (4): 309–11. PMID 6241861.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  48. Velpeau A. Aissele. In: Bechet Jeune Z: Dictionnaire de médecine, on Repertoire Générale des Sciences Medicals sous le Rapport Theorique et Pratique. 1839.
  49. Verneuil AS (1854). "Etudes sur les tumeurs de la peau et quelques maladies de glandes sudoripares". Archives of General Medicine (in French). 94: 693–705. Unknown parameter |trans_title= ignored (help)CS1 maint: unrecognized language (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  50. Schiefferdecker B (1922). Die Hautdrüsen der Menschen und der Säugetiere, ihre histologische und rassenanatomische Bedeutung sowie die muscularis sexualis. Stuttgart: Schweizerbart E. Unknown parameter |trans_title= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>[page needed]
  51. Pillsbury DM, Shelley WB, Kligmann AM (1956). "Bacterial infections of the skin". In Pillsbury DM (ed.). Dermatoloy (1st ed.). Philadelphia. pp. 482–9.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  52. Plewig, Gerd; Kligman, Albert M. (1975). "Acne Conglobata". In Plewig, Gerd; Kligman, Albert M. (eds.). Acne: Morphogenesis and Treatment. pp. 168–203. doi:10.1007/978-3-642-96246-2_11. ISBN 978-3-642-96246-2.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  53. 53.0 53.1 Plewig G, Steger M (1989). "Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa)". In Marks R, Plewig G (ed.). Acne and Related Disorders. London: Martin Dunitz. pp. 345–57.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  54. Sellheyer K; Krahl D. (2005). ""Hidradenitis suppurativa" is acne inversa! An appeal to (finally) abandon a misnomer". International Journal of Dermatology. 44 (7): 535–40. doi:10.1111/j.1365-4632.2004.02536.x. PMID 15985019.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  55. Bazex, J, Bayle, P, San, B. (2007). "Hidradenitis suppurativa is acne inversa". International Journal of Dermatology. 46 (3): 330. doi:10.1111/j.1365-4632.2007.02872.x. PMID 17343599.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  56. Scheinfeld N (2006). "Hidradenitis should not be renamed acne inversa". Dermatol. Online J. 12 (7): 6. PMID 17459292.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  57. Verneuil AS (1854). "Etudes sur les tumor de la peau". Arch Gen Med (in French). 94: 693.CS1 maint: unrecognized language (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  58. Yu C. and Cook M. (1990). "Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands". Br J Dermatology. 122 (6): 763–69. doi:10.1111/j.1365-2133.1990.tb06264.x. PMID 2369556.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  59. Boer J, Weltevreden EF (1996). "Hidradenitis suppurativa or Acne inversa. A clinicopathological study of early lesions". Br J Dermatol. 135 (5): 721–5. doi:10.1111/j.1365-2133.1996.tb03880.x. PMID 8977671.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>

External links